KMDA Stock Analysis: Buy, Sell, or Hold?
KMDA - Kamada Ltd
$8.24
0.22 (2.74%)
▲
5d:
+8.71%
30d:
+18.39%
90d:
+5.37%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When KMDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: KMDA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: KMDA shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$15.95
Based on 13.2% avg growth
INTRINSIC VALUE TODAY
$9.90
16.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: KMDA is currently trading at $8.24, which is considered extended relative to its 30-day fair value range of $6.92 to $7.63. The stock's valuation (Forward PE: 13.8) is in line with its historical norms (14.5). Remarkably, the market is currently pricing in an annual earnings decline of 1.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, KMDA is in a strong downtrend. The price is approaching resistance at $8.25. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: KMDA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.50 (+63.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KMDA is in a strong downtrend. The price is approaching resistance at $8.25. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: KMDA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.50 (+63.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$6.92 -
$7.63
Company Quality Score
30/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
23.8%
All Signals
- BEARISH: Price extended above range (+8.0% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 63.8% below Wall St target ($13.50)
- WARNING: Composite score 30/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$6.92 -
$7.63
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$6.85
Resistance Level
$8.25
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.81
Wall Street Target
$13.50
(+63.8%)
Revenue Growth (YoY)
2.8%
Profit Margin
11.2%
Valuation Discount vs History
-1.6% cheaper
PE vs Historical
13.8 vs 14.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.6%
(market-implied from PE analysis)
1-Year Target
$8.11
(-2%)
2-Year Target
$7.98
(-3%)
3-Year Target
$7.85
(-5%)
3-Yr Target (if PE normalizes)
(PE: 14→15)
$8.24
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 22.4%)
$21.96
(+167%)
Base:
(SPY PE: 13.8, Growth: 22.4%)
$15.11
(+83%)
Bear:
(PE: 11.7, Growth: 22.4%)
$12.84
(+56%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 20.56 | Current EPS (TTM): $0.39
Bull Case
$13.50
(+64%)
Analyst growth 53.0%, PE expands to 22.6
Base Case
$12.27
(+49%)
Market implied 53.0%, PE stable at 20.6
Bear Case
$5.45
(-34%)
Severe decline -20.0%, PE contracts to 17.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 13.8 to 14.5
Stabilization Target:
$8.65
(+5.0%)
PE Expansion Potential:
+5.0%
Share & Embed Analysis
Last updated: August 23, 2026 11:07 PM ET
Data refreshes hourly during market hours. Next update: 12:07 AM
Data refreshes hourly during market hours. Next update: 12:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KMDA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 56 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 43 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 48 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 55 HOLD |
